Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint
Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
YH002004: CTU A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors
Gurney, H., Chester, C. & Chapman, N.
2/05/22 → 18/04/27
Project: Research
-
HP518-CS-001: A Phase 1 open-label study to assess the safety, pharmacokinetics and anti-tumor activity of oral HP518 in patients with metastatic castration-resistant prostate cancer
Gurney, H. & Chapman, N.
17/01/22 → 13/12/26
Project: Research
-
CAPTIVATE: Randomized, Open label, Phase 3 Study of Acapatamab vs Standard of Care in Metastatic Castration resistant Prostate Cancer (CAPTIVATE)
Gurney, H., Zhang, A., Chapman, N. & Tan, P.
1/11/21 → 2/03/26
Project: Research
-
SAMETA: A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Gurney, H., Zhang, A. & Chapman, N.
6/09/21 → 4/06/26
Project: Research
Research Outputs
-
Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region
Eto, M., Lee, J-L., Chang, Y-H., Gao, S., Singh, M. & Gurney, H., 3 Mar 2022, (E-pub ahead of print) In: Asia-Pacific Journal of Clinical Oncology. 13 p.Research output: Contribution to journal › Review article › peer-review
Open Access -
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Gurney, H., Kollmannsberger, C. K., Grimm, M-O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B. I. & 5 others, , 1 Jun 2022, In: Cancer. 128, 11, p. 2085-2097 13 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus)10 Downloads (Pure) -
First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C. K., Gurney, H., Grimm, M-O., Tomita, Y., Castellano, D., Rini, B. I., Choueiri, T. K., Leung, D., Saggi, S. S., Lee, C. W. & 2 others, , Mar 2022, In: European Urology. 81, 3, p. 266-271 6 p.Research output: Contribution to journal › Article › peer-review
2 Citations (Scopus) -
Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients
Birzniece, V., Lam, T., McLean, M., Reddy, N., Shahidipour, H., Hayden, A., Gurney, H., Stone, G., Hjortebjerg, R. & Frystyk, J., 29 Apr 2022, In: Endocrine Connections. 11, 4, 11 p., e210375.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Smith, M. R., Scher, H. I., Sandhu, S., Efstathiou, E., Lara, P. N., Yu, E. Y., George, D. J., Chi, K. N., Saad, F., Ståhl, O., Olmos, D., Danila, D. C., Mason, G. E., Espina, B. M., Zhao, X., Urtishak, K. A., Francis, P., Fizazi, K. & GALAHAD investigators, Mar 2022, In: The Lancet Oncology. 23, 3, p. 362-373 12 p.Research output: Contribution to journal › Article › peer-review
7 Citations (Scopus)